UNSPSC 51421501: Fluticasone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H27F3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUT2W21N7U, chemically known as s-(fluoromethyl) 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-propionate but generally known as fluticasone, which bears US NIH Compound Identifier 54580. European Medicines Agency schedules Fluticasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07760MIG.

UNSPSC 51421501 Fluticasone is a Commodity code that in practice sees minimal recent state and local procurement activity, with the two most recent opportunities in the dataset bearing no meaningful connection to fluticasone procurement. Seminole County, Florida posted an IFB on June 30, 2026 for naloxone and drug deactivation systems—a public health emergency-response product fundamentally distinct from fluticasone, a corticosteroid inhaler used for chronic respiratory disease management. The Texas Health and Human Services Commission issued an RFI in April 2026 regarding direct-to-manufacturer prescription programs, which addresses pharmacy benefit management strategy rather than procurement of any specific pharmaceutical product. Neither opportunity reflects actual demand for fluticasone products under this code.

The code shows no identifiable recent state and local procurement activity for fluticasone itself. The mismatch between the code's nominal scope and the actual content of posted opportunities suggests either inconsistent tagging of submissions in the state and local procurement system or extremely limited current demand for fluticasone through formal competitive solicitations at the state, county, municipal, and special-district levels. Business development professionals should treat this code as inactive in the near term and monitor it for signs of future procurement intent, particularly through state Medicaid agencies, state health departments, school districts with respiratory health programs, or county public health authorities that might consolidate inhaled corticosteroid purchases.